Quince Therapeutics (QNCX) Interest Expenses (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Interest Expenses of $29000.0 for Q1 2026, down 45.28% year-over-year from $53000.0 in Q1 2025, and down 50.0% quarter-over-quarter from $58000.0 in Q4 2025.
Quince Therapeutics (QNCX) Interest Expenses (2018 - 2026) Analysis & Trends
Quince Therapeutics' Interest Expenses history runs 9 years deep, the most recent figure standing at $29000.0 for Q1 2026.
- In Q1 2026, Interest Expenses fell 45.28% year-over-year to $29000.0; the TTM figure through Mar 2026 stood at $58.7 million (up 203.33% YoY), while the FY2025 annual figure was $85.1 million, down 7.02% from the prior year.
- Interest Expenses for Q1 2026 stood at $29000.0, down from $58000.0 in the prior quarter.
- The five-year high for Interest Expenses was $58.6 million in Q2 2025, with the low at -$56.9 million in Q4 2023.
- The 5-year median for Interest Expenses is $667000.0 (2024), against an average of $856933.3.
- Peak annual rise in Interest Expenses reached 8685.61% in 2025, while the deepest fall reached 92.7% in 2025.
- Quince Therapeutics' Interest Expenses stood at $754000.0 in 2022, then sank by 7646.42% to -$56.9 million in 2023, then jumped by 101.15% to $655000.0 in 2024, then sank by 91.15% to $58000.0 in 2025, then slumped by 50.0% to $29000.0 in 2026.
- Business Quant data shows QNCX's Interest Expenses at $29000.0 in Q1 2026, $58000.0 in Q4 2025, and $128000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,000.00 |
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | 58,000.00 |
| Dec 31, 2025 | 58,000.00 |
| Sep 30, 2025 | 128,000.00 |
| Sep 30, 2025 | 128,000.00 |
| Jun 30, 2025 | 58.60 Mn |
| Jun 30, 2025 | 58.60 Mn |
| Mar 31, 2025 | 53,000.00 |
| Mar 31, 2025 | 53,000.00 |
| Sep 30, 2024 | 655,000.00 |
| Sep 30, 2024 | 655,000.00 |
| Jun 30, 2024 | 667,000.00 |
| Jun 30, 2024 | 667,000.00 |
| Mar 31, 2024 | 726,000.00 |
| Mar 31, 2024 | 726,000.00 |
| Dec 31, 2023 | -56.90 Mn |
| Dec 31, 2023 | -56.90 Mn |
| Sep 30, 2023 | 245,000.00 |
| Sep 30, 2023 | 245,000.00 |